FAM
Fred Alger Management Portfolio holdings
AUM
$22.3B
1-Year Return
57.87%
This Quarter Return
+18.44%
1 Year Return
+57.87%
3 Year Return
+264.72%
5 Year Return
+406.03%
10 Year Return
+1,631.73%
AUM
$18.7B
AUM Growth
+$249M
(+1.3%)
Cap. Flow
-$1.84B
Cap. Flow
% of AUM
-9.83%
Top 10 Holdings %
Top 10 Hldgs %
31.1%
Holding
586
New
70
Increased
194
Reduced
228
Closed
71
Top Buys
| 1 |
Martin Marietta Materials
MLM
|
$184M |
| 2 |
Meta Platforms (Facebook)
META
|
$171M |
| 3 |
Apple
AAPL
|
$167M |
| 4 |
GFL Environmental
GFL
|
$123M |
| 5 |
Mercado Libre
MELI
|
$117M |
Top Sells
| 1 |
NextEra Energy, Inc.
NEE
|
$167M |
| 2 |
Eli Lilly
LLY
|
$159M |
| 3 |
McKesson
MCK
|
$152M |
| 4 |
Microsoft
MSFT
|
$151M |
| 5 |
Alphabet (Google) Class C
GOOG
|
$142M |
Sector Composition
| 1 | Technology | 34.63% |
| 2 | Healthcare | 20.74% |
| 3 | Consumer Discretionary | 12.81% |
| 4 | Industrials | 10.52% |
| 5 | Communication Services | 6.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Biomea Fusion
BMEA
$114M
| $518K | ﹤0.01% |
+16,689
| New | +$518K |
|
402
10x Genomics
TXG
$1.72B
| $492K | ﹤0.01% |
+8,820
| New | +$492K |
|
403
Synopsys
SNPS
$110B
| $473K | ﹤0.01% |
1,224
-619
| -34% | -$239K |
|
404
Rockwell Automation
ROK
$38B
| $470K | ﹤0.01% |
1,603
| – | – |
|
405
Immunovant
IMVT
$2.98B
| $457K | ﹤0.01% |
+29,443
| New | +$457K |
|
406
MaxCyte
MXCT
$148M
| $454K | ﹤0.01% |
91,759
| – | – |
|
407
Arcellx
ACLX
$4.02B
| $443K | ﹤0.01% |
14,374
-4,059
| -22% | -$125K |
|
408
Viking Therapeutics
VKTX
$2.98B
| $443K | ﹤0.01% |
+26,597
| New | +$443K |
|
409
iRhythm Technologies
IRTC
$5.86B
| $430K | ﹤0.01% |
+3,467
| New | +$430K |
|
410
CyberArk
CYBR
$23.2B
| $380K | ﹤0.01% |
2,567
-59,368
| -96% | -$8.79M |
|
411
Allegion
ALLE
$14.7B
| $350K | ﹤0.01% |
3,277
| – | – |
|
|
EBIX
412
DELISTED
Ebix Inc
EBIX
| $321K | ﹤0.01% |
24,337
-220,943
| -90% | -$2.91M |
|
413
Pool Corp
POOL
$12.3B
| $319K | ﹤0.01% |
932
| – | – |
|
414
Trimble
TRMB
$19B
| $310K | ﹤0.01% |
5,921
-1,432
| -19% | -$75.1K |
|
415
Quanta Services
PWR
$54.8B
| $293K | ﹤0.01% |
1,759
+129
| +8% | +$21.5K |
|
416
Nuvalent
NUVL
$5.94B
| $280K | ﹤0.01% |
10,724
-1,064
| -9% | -$27.8K |
|
417
Karyopharm Therapeutics
KPTI
$59.1M
| $270K | ﹤0.01% |
+4,628
| New | +$270K |
|
418
Protagonist Therapeutics
PTGX
$3.7B
| $267K | ﹤0.01% |
+11,605
| New | +$267K |
|
419
Goosehead Insurance
GSHD
$2.11B
| $261K | ﹤0.01% |
4,996
-4,347
| -47% | -$227K |
|
420
Immunocore
IMCR
$1.81B
| $250K | ﹤0.01% |
5,047
-3,312
| -40% | -$164K |
|
421
ADC Therapeutics
ADCT
$394M
| $246K | ﹤0.01% |
+125,985
| New | +$246K |
|
422
Guardant Health
GH
$7.42B
| $234K | ﹤0.01% |
10,000
-478
| -5% | -$11.2K |
|
423
Harrow
HROW
$1.36B
| $205K | ﹤0.01% |
+9,685
| New | +$205K |
|
424
Terns Pharmaceuticals
TERN
$628M
| $193K | ﹤0.01% |
+16,276
| New | +$193K |
|
425
Fair Isaac
FICO
$36.5B
| $171K | ﹤0.01% |
243
+72
| +42% | +$50.6K |
|